Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906381 | 1.00 | MAP2K1 (0.50) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24906368 | 1.00 | MAP2K1 (0.50) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045817 | 0.92 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045816 | 0.92 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24906269 | 0.88 | MAP2K1 (0.47) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL24906169 | 0.88 | MAP2K1 (0.40) | MAP2K1MAP2K2 | |
| SCHEMBL24350862 | 0.86 | MAP2K1 (0.50) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24906179 | 0.85 | FLT1 (0.38) | MAP2K1MAP2K2 | |
| SCHEMBL24906369 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24088840 | 0.84 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |